|
Mustang Bio, Inc. and City of Hope recently announced the first patient has been dosed in a clinical trial to establish the safety and feasibility of administering MB-101 (autologous IL13Rα2-CAR T cells) to patients with leptomeningeal brain tumors (eg, glioblastoma, ependymoma, or medulloblastoma). The trial will enroll up to 30 patients and is taking place at City of Hope, where this chimeric antigen receptor T (CAR T) cell therapy was initially developed. Even though it is a single center clinical trial,
» Read more about: Mustang Bio & City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial »
|